Home R&D Page 3

R&D

Positive interim results from Celltrion’s Phase I trial of anti-COVID-19 candidate
Featured

Positive interim results from Celltrion’s Phase I trial of anti-COVID-19 candidate

Dominic Cuthbert -
0
Sanofi & GSK initiate Phase 1/2 trial of COVID-19 vaccine candidate
Featured

Sanofi & GSK initiate Phase 1/2 trial of COVID-19 vaccine candidate

Dominic Cuthbert -
0
Study confirms metyrapone is effective, safe for treating endogenous Cushing’s Syndrome
Featured

Study confirms metyrapone is effective, safe for treating endogenous Cushing’s Syndrome

Dominic Cuthbert -
0
Study demonstrates value of deep learning for imputation of drug discovery data
Featured

Study demonstrates value of deep learning for imputation of drug discovery data

Dominic Cuthbert -
0
Gilead licences novel immunotherapy programme
Featured

Gilead licences novel immunotherapy programme

Dominic Cuthbert -
0
PhoreMost and XtalPi sign AI-based pharmaceutical drug discovery collaboration agreement
Featured

PhoreMost and XtalPi sign AI-based pharmaceutical drug discovery collaboration agreement

Tess Egginton -
0
New collaboration to identify novel treatments for alcoholic hepatitis 
Featured

New collaboration to identify novel treatments for alcoholic hepatitis 

Tess Egginton -
0
AstraZeneca’s COVID-19 vaccine expands into Phase III human trials
Featured

AstraZeneca’s COVID-19 vaccine expands into Phase III human trials

Dominic Cuthbert -
0
Engitix to develop anti-fibrotic therapies in liver disease alongside Takeda
Featured

Engitix to develop anti-fibrotic therapies in liver disease alongside Takeda

Dominic Cuthbert -
0
AbbVie & Harvard to tackle emergent viral diseases
Featured

AbbVie & Harvard to tackle emergent viral diseases

Dominic Cuthbert -
0
1234...176Page 3 of 176

© 2020 Part of the Business Link Magazine Group. Armstrong House, Armstrong Street, Grimsby,
North East Lincolnshire, DN31 2QE

About Us

Popular Category

Editor Picks